印度单中心对血友病A抑制物患者进行免疫耐受诱导治疗的经验
Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India.
作者信息
Seth Tulika
机构信息
Room 5017, Teaching Block, AIIMS, Ansari Nagar, New Delhi, 110029 India.
出版信息
Indian J Hematol Blood Transfus. 2020 Jul;36(3):458-463. doi: 10.1007/s12288-019-01218-2. Epub 2019 Nov 4.
Abstract
The availability of clotting factor concentrates of both factor VIII and factor IX have improved hemophilia treatment to a great extent. Many more improvements like physiotherapy, and comprehensive care are needed to give better care. One important complication that occurs, but is often set aside is the development of inhibitors. When an inhibitor develops in a patient of severe hemophilia then the care becomes more difficult and expensive. Eradication of the inhibitor is possible by Immune tolerance induction (ITI), this paper explains some important essential factors and practical issues during my experience with ITI.
摘要
凝血因子 VIII 和凝血因子 IX 浓缩剂的可获得性在很大程度上改善了血友病的治疗。还需要更多的改进措施，如物理治疗和综合护理，以提供更好的治疗。一个经常被忽视的重要并发症是抑制剂的产生。当重度血友病患者体内产生抑制剂时，治疗会变得更加困难且昂贵。通过免疫耐受诱导（ITI）可以消除抑制剂，本文将阐述我在 ITI 治疗过程中的一些重要基本因素和实际问题。
相似文献
1
Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India.印度单中心对血友病A抑制物患者进行免疫耐受诱导治疗的经验
Indian J Hematol Blood Transfus. 2020 Jul;36(3):458-463. doi: 10.1007/s12288-019-01218-2. Epub 2019 Nov 4.
2
Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience.血友病低剂量免疫耐受诱导：单中心经验
J Pediatr Hematol Oncol. 2019 Aug;41(6):e355-e358. doi: 10.1097/MPH.0000000000001391.
3
Inhibitor antibodies to factor VIII and factor IX: management.针对凝血因子VIII和凝血因子IX的抑制性抗体：管理
Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821.
4
New protocol for immune tolerance induction in acquired hemophilia.获得性血友病免疫耐受诱导的新方案。
Haematologica. 2000 Oct;85(10 Suppl):64-8.
5
Immune tolerance induction in patients with severe hemophilia A with inhibitors.在患有抑制物的重度甲型血友病患者中诱导免疫耐受。
Blood Res. 2015 Dec;50(4):248-53. doi: 10.5045/br.2015.50.4.248. Epub 2015 Dec 21.
6
Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.血友病患者接受免疫耐受诱导方案联合免疫抑制剂以消除抑制剂的临床骨健康护理。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620913951. doi: 10.1177/1076029620913951.
7
Toward optimal therapy for inhibitors in hemophilia.血友病中抑制物的优化治疗
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):364-71. doi: 10.1182/asheducation-2014.1.364. Epub 2014 Nov 18.
8
Toward optimal therapy for inhibitors in hemophilia.针对血友病抑制剂的最佳治疗方法。
Blood. 2014 Nov 27;124(23):3365-72. doi: 10.1182/blood-2014-05-577643.
9
10
Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.通过大剂量免疫球蛋白诱导免疫耐受，早期根除先天性血友病A患者体内的凝血因子VIII抑制物。
Int J Hematol. 2016 Apr;103(4):473-7. doi: 10.1007/s12185-016-1943-0. Epub 2016 Feb 1.
引用本文的文献
1
Nonfactor Therapies in Hemophilia A: An Essential Drug Entity.甲型血友病的非凝血因子疗法：一种重要的药物实体。
Cureus. 2024 Oct 3;16(10):e70763. doi: 10.7759/cureus.70763. eCollection 2024 Oct.
2
Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab.印度血友病A管理的专家意见：艾美赛珠单抗的作用
Cureus. 2024 Apr 24;16(4):e58941. doi: 10.7759/cureus.58941. eCollection 2024 Apr.
3
Management of haemophilia A with inhibitors: A regional cross-talk.血友病 A 伴抑制物的治疗：区域间对话。
Haemophilia. 2022 Nov;28(6):950-961. doi: 10.1111/hae.14638. Epub 2022 Jul 22.
本文引用的文献
1
Immune tolerance induction: What have we learned over time?免疫耐受诱导：随着时间的推移，我们学到了什么？
Haemophilia. 2018 Apr;24 Suppl 3:3-14. doi: 10.1111/hae.13445.
2
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.实验室检测血友病患者的因子 VIII 和 IX 抑制剂：综述。
Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15.
3
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.血友病A治疗中对凝血因子VIII免疫耐受的创新方法。
Front Immunol. 2017 Nov 24;8:1604. doi: 10.3389/fimmu.2017.01604. eCollection 2017.
4
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
5
Extended half-life factor VIII for immune tolerance induction in haemophilia.用于血友病免疫耐受诱导的延长半衰期因子VIII。
Haemophilia. 2016 Nov;22(6):e552-e554. doi: 10.1111/hae.13064. Epub 2016 Sep 19.
6
Management of Haemophilia in Developing Countries: Challenges and Options.发展中国家血友病的管理：挑战与选择
Indian J Hematol Blood Transfus. 2016 Sep;32(3):347-55. doi: 10.1007/s12288-015-0562-x. Epub 2015 Jun 18.
7
Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.使用单一血浆源性FVIII/VWF产品成功诱导免疫耐受治疗后甲型血友病患者的长期结局：长期免疫耐受诱导（ITI）研究
Haemophilia. 2016 Nov;22(6):859-865. doi: 10.1111/hae.12986. Epub 2016 Jun 22.
8
Costs and utilization of treatment in patients with hemophilia.血友病患者的治疗成本与利用情况
BMC Health Serv Res. 2015 Oct 26;15:484. doi: 10.1186/s12913-015-1134-3.
9
US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.美国血友病A合并抑制物患者免疫耐受诱导指南。
Haemophilia. 2015 Sep;21(5):559-67. doi: 10.1111/hae.12730. Epub 2015 Jun 2.
10
Pearls and pitfalls in factor inhibitor assays.凝血因子抑制物检测中的要点与陷阱
Int J Lab Hematol. 2015 May;37 Suppl 1:52-60. doi: 10.1111/ijlh.12352.
Zotero 插件